Recent Updates
Recently added Catalysts
INO Positive Sentiment Score: 70/100

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

Key Takeaway: INOVIO Pharmaceuticals, a biotechnology company specialized in DNA medicines, announced that its President and CEO, Dr. Jacqueline Shea, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023. The presentation will include a fireside chat format, allowing for insights into the company's developments. Additionally, the management team will engage in one-on-one meetings with registered investors during the conference. A webcast of the event will be available, ensuring broader access to the presentation.

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO is presenting at a significant healthcare conference, indicating strong industry engagement.
  • The focus of the company on DNA medicines suggests innovative approaches to healthcare.
  • One-on-one meetings with investors highlight confidence in INOVIO’s future prospects.

Full Press Release Details

PLYMOUTH MEETING, Pa., March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference.
Oppenheimer 33rd Annual Healthcare Conference
Date: Monday, March 13, 2023
Format: Fireside Chat
During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.
A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
Media: Jennie Willson (267) 429-8567 [email protected]
Investors: Thomas Hong (267) 440-4298 [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What is INOVIO focused on developing?

INOVIO specializes in DNA medicines for HPV-related diseases, cancer, and infections.

When will Dr. Jacqueline Shea present?

Dr. Shea will present at the Oppenheimer Conference on March 13, 2023.

How can I watch the presentation?

The presentation will be available on INOVIO's Investor Relations Events page.

What is CELLECTRA®?

CELLECTRA® is INOVIO's device for delivering DNA medicines to stimulate immune responses.

Who can I contact for more information?

Media inquiries can reach Jennie Willson, and investors can contact Thomas Hong.

Last updated: Mar 3, 2023